Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ASND
ASND
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ASND News
Ascendis Pharma Reports Three-Year Data on TransCon PTH Efficacy
Jun 13 2026
Newsfilter
Ascendis Pharma Reports Five-Year Data on TransCon PTH for Hypoparathyroidism
Jun 12 2026
NASDAQ.COM
Ascendis Pharma Reports Sustained Efficacy of Yorvipath Over Five Years
Jun 11 2026
seekingalpha
Ascendis Pharma to Present New Data at ENDO 2026
Jun 08 2026
Newsfilter
Siren Fully Liquidates Ascendis Pharma Holdings
May 14 2026
Fool
Ascendis Pharma to Announce Q1 Earnings on May 7
May 06 2026
seekingalpha
Ascendis Pharma Announces Redemption of Convertible Notes
Apr 21 2026
Newsfilter
Ascendis Pharma to Directly List Ordinary Shares on Nasdaq
Apr 12 2026
Yahoo Finance
Ascendis Pharma Plans Direct Listing on Nasdaq
Apr 08 2026
Newsfilter
Ascendis Pharma's YUVIWEL Receives FDA Orphan Drug Exclusivity
Apr 07 2026
NASDAQ.COM
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
Mar 19 2026
seekingalpha
Ascendis Pharma Reports Positive Phase 2 Trial Results for TransCon hGH
Mar 18 2026
NASDAQ.COM
FDA Grants Approvals for Multiple New Therapies
Mar 06 2026
NASDAQ.COM
Ascendis Pharma Plans 2026 U.S. Launch of YUVIWEL Following FDA Approval
Mar 05 2026
Yahoo Finance
Ascendis Pharma A/S (ASND.US) Officer Plans to Sell $4.44 Million in Common Stock via Form 144
Mar 02 2026
moomoo
Ascendis Pharma Receives FDA Approval for New Drug
Mar 02 2026
Benzinga
Show More News
